GPI在RA诊疗中的价值及复方丹参注射液对其的干预
|
摘要
1目的
1.1检测6-磷酸葡萄糖异构酶(GPI)抗原在类风湿性关节炎(RA)患者、非RA自身免疫性疾病患者以及非免疫性疾病患者、健康体检者血清中的浓度,以探讨其在RA诊断中的临床应用价值。
1.2探讨血清中GPI、抗环瓜氨酸肽抗体(抗CCP抗体)、抗角质蛋白抗体(AKA)及类风湿因子(RF)4种自身抗体联合检测在RA中的诊断意义。
1.3将RA患者血清中GPI与RF、血沉(ESR).C-反应蛋白(CRP)做比较,探讨GPI与各指标之间的相关性。
1.4检测20例RA患者治疗前后GPI水平、RF.ESR.CRP的浓度变化,探讨GPI对RA病情变化的反应及复方丹参注射液对GPI的影响。
2方法
2.1收集符合诊断标准和排除标准的RA患者53例,其他自身免疫性疾病患者35例,非免疫性疾病患者30例,健康体检者60例,采用酶联免疫吸附法定量检测各组血清中的GPI浓度,将结果进行统计学比较。
2.2收集符合诊断标准和排除标准的RA患者53例及非RA患者65例,分别采用酶联免疫吸附法检测GPI、抗CCP,间接免疫荧光法检测AKA,免疫速率散射比浊法检测RF,总结出各自身抗体单独检测以及联合检测对RA诊断的敏感性及特异性。
2.3收集符合诊断标准和排除标准的RA患者53例,分别采用酶联免疫吸附法检测GPI,免疫速率散射比浊法检测RF.CPR,魏氏法检测ESR,将结果进行统计学比较。
2.4收集符合诊断标准和排除标准的RA患者20例,检测治疗前后的GPI水平、RF、ESR. CRP,将治疗前后结果变化进行统计学比较；治疗前后GPI浓度变化与外院GPI浓度变化进行比较。
3结果
3.1 RA组GPI浓度3.65±2.87 ug/ml,阳性率79.25%,非RA自身免疫病组为0.96±1.74 ug/ml,阳性率40%,非自身免疫病组GPI浓度0.40±0.99 ug/ml,阳性率20%,健康对照组中阳性率5%。RA组GPI水平明显高于其它两组,RA组与非RA自身免疫病组、非自身免疫病组比较有显著性差异(P<0.01)；非RA自身免疫病组与非自身免疫病组比较无统计学差异(P>0.05)。
3.2 GPI在RA患者中敏感性79.25%,特异性69.23%,抗CCP 56.6%、96.92%,AKA 32.08%.96.92%,RF 71.7、%89.23%,GPI与抗CCP.RF和/或AKA联合检测则阳性率提高到88.68%,特异性高达98.46%。
3.3 GPI与RF相比,r值为0.6527,P<0.01,两者之间有显著相关性；而GPI与血沉、C-反应蛋白相比均无相关性(P>0.05)。
3.4 20例RA患者经治疗后主要症状较前明显改善,治疗前后GPI水平、RF、血沉、C-反应蛋白比较均无显著性差异；治疗后GPI含量有下降趋势但无统计学意义,与外院研究结果无显著差异。
4结论
4.1 GPI抗原的检测在RA临床诊断、鉴别诊断中具有一定的价值,很可能成为RA临床诊断的一个新指标。
4.2 GPI、抗CCP、AKA、RF4种抗体联合检测对RA有较高的敏感性和特异性,可提高RA的诊断率。
4.3 GPI与RF有显著相关性,由于RF对RA活动性判断有明确的意义,由此推断GPI对RA的诊断及活动性的判断有很大的临床应用价值,有可能和CRP一样,成为RA活动的指标之一
4.4本研究结果显示GPI与RA疗效无显著相关性,对RA疗效评价意义不大；经复方丹参注射液治疗后患者血清中GPI阳性率明显降低且含量有降低趋势,复方丹参注射液对GPI有一定的影响。
1 Objects
1.1 To study serum glucose-6 phosphate isomerase(GPI) level from RA patients, other rheumatologic patients, non-rheumatologic patients and healthy controls. Discuss the role of glucose-6 phosphate isomerase in diagnosis of RA.
1.2 To assess the diagnostic significance of serum GPI, anti-Cyclic Citrullinated Peptide antibody(anti-CCP), anti-keratin antibody(AKA) and rheumatoid factor(RF) in the diagnosis of RA.
1.3 To compare serum GPI, RF, erythrocyte sedimentation rate(ESR), C-reative protein(CRP) of RA patients. Evaluate the relationship among GPI and other factors.
1.4 To study the variation of GPI,RF, ESR, CRP before and after treatment. Evaluate the role of GPI in curative effect evaluation of RA. Evaluate the effect of compound salvia m iltiorrhizal injection on GPI.
2 Methods
2.1 Used Enzyme-Linked Immuno Sorbent Assay to exam serum GPI level from 53 RA patients,35 other rheumatologic patients,30·non-rheumatologic patients and 60 healthy controls.The result of this study was compared.
2.2 Used Enzyme-Linked Immuno Sorbent Assay to exam serum GPI level, anti-CCP, used indirect immunofluoresent assay to exam AKA, used turbidimetric immunoassay method to exam RF from 53 patients of RA. Sum up the sensitivity and specificity for diagnosis of RA.
2.3 Used Enzyme-Linked Immuno Sorbent Assay to exam serum GPI level,used turbidimetric immunoassay method to exam RF and CRP, used westergren to exam ESR from 53 patients of RA. Sum up and compare the result.
2.4 To exam serum GPI level, RF, ESR, CRP from 20 patients of RA before and after the treatment and compare the result. To compare serum GPI level before and after the treatment with othe hospital.
3 Results
3.1 Serum GPI level and the GPI positive rate from RA patients were 3.65±2.87ug/ml and 79.25%, from other rheumatologic patients were 0.96±1.74ug/ml and 40%, from non-rheumatologic patients were 0.40±0.99ug/ml and 20%. The GPI positive rate from healthy controls was 5%. Serum GPI level from RA patients was significantly higher than those from other rheumatologic patients and non-rheumatologic patients. There were significant difference among RA patients and other rheumatologic patients, non-rheumatologic patients. There were no difference between rheumatologic patients and non-rheumatologic patients.
3.2 The sensitivity and specificity of GPI for diagnosis of RA were 79.25% and 69.23%;anti-CCP were 56.6% and 96.92%; AKA were 32.0% and 96.92%; RF were 71.7% and 89.23%. The sensitivity and specificity of the combined detection of GPI,anti-CCP and RF and/or AKA were 88.68% and 100%.
3.3 Compared with RF, the r value was 0.6527. There were significant relationship between GPI and RF (P<0.01). While there were no relationship among GPI and ESR、CRP(P>0.05).
3.4 The main clinical symptoms of the 20 RA patients were improved significantly after the treatment. Serum GPI level, ESR and CRP had no difference between before and after the treatment. Serum GPI level was degraded significantly but was conformity. Compared with other clinical research, the changement of serum GPI level was conformity.
4 Conclusions
4.1 GPI holds great promise as a diagnosis and differential diagnosis tool for RA. It may be a new index for diagnosis of RA.
4.2 The combined detection of GPI, anti-CCP, AKA and RF have high sensitivity and specificity in diagnosis of RA. Thus the combined detection of these four antibodies may help the diagnosis of RA.
4.3 GPI is shown to be significantly related to RF. RF plays a great role on the activity of RA. Thus, GPI holds great promise as a diagnosis tool for RA and its activity. It may be one of the index for activity of RA such as CRP.
4.4 GPI is not shown to be significantly related in curative effect evaluation to RA. The GPI positive rate and serum GPI level from 20 RA patients is degraded significantly after the treatment of compound salvia m iltiorrhizal injection. Compound salvia m iltiorrhizal injection has certain impact on GPI.
1.1检测6-磷酸葡萄糖异构酶(GPI)抗原在类风湿性关节炎(RA)患者、非RA自身免疫性疾病患者以及非免疫性疾病患者、健康体检者血清中的浓度,以探讨其在RA诊断中的临床应用价值。
1.2探讨血清中GPI、抗环瓜氨酸肽抗体(抗CCP抗体)、抗角质蛋白抗体(AKA)及类风湿因子(RF)4种自身抗体联合检测在RA中的诊断意义。
1.3将RA患者血清中GPI与RF、血沉(ESR).C-反应蛋白(CRP)做比较,探讨GPI与各指标之间的相关性。
1.4检测20例RA患者治疗前后GPI水平、RF.ESR.CRP的浓度变化,探讨GPI对RA病情变化的反应及复方丹参注射液对GPI的影响。
2方法
2.1收集符合诊断标准和排除标准的RA患者53例,其他自身免疫性疾病患者35例,非免疫性疾病患者30例,健康体检者60例,采用酶联免疫吸附法定量检测各组血清中的GPI浓度,将结果进行统计学比较。
2.2收集符合诊断标准和排除标准的RA患者53例及非RA患者65例,分别采用酶联免疫吸附法检测GPI、抗CCP,间接免疫荧光法检测AKA,免疫速率散射比浊法检测RF,总结出各自身抗体单独检测以及联合检测对RA诊断的敏感性及特异性。
2.3收集符合诊断标准和排除标准的RA患者53例,分别采用酶联免疫吸附法检测GPI,免疫速率散射比浊法检测RF.CPR,魏氏法检测ESR,将结果进行统计学比较。
2.4收集符合诊断标准和排除标准的RA患者20例,检测治疗前后的GPI水平、RF、ESR. CRP,将治疗前后结果变化进行统计学比较；治疗前后GPI浓度变化与外院GPI浓度变化进行比较。
3结果
3.1 RA组GPI浓度3.65±2.87 ug/ml,阳性率79.25%,非RA自身免疫病组为0.96±1.74 ug/ml,阳性率40%,非自身免疫病组GPI浓度0.40±0.99 ug/ml,阳性率20%,健康对照组中阳性率5%。RA组GPI水平明显高于其它两组,RA组与非RA自身免疫病组、非自身免疫病组比较有显著性差异(P<0.01)；非RA自身免疫病组与非自身免疫病组比较无统计学差异(P>0.05)。
3.2 GPI在RA患者中敏感性79.25%,特异性69.23%,抗CCP 56.6%、96.92%,AKA 32.08%.96.92%,RF 71.7、%89.23%,GPI与抗CCP.RF和/或AKA联合检测则阳性率提高到88.68%,特异性高达98.46%。
3.3 GPI与RF相比,r值为0.6527,P<0.01,两者之间有显著相关性；而GPI与血沉、C-反应蛋白相比均无相关性(P>0.05)。
3.4 20例RA患者经治疗后主要症状较前明显改善,治疗前后GPI水平、RF、血沉、C-反应蛋白比较均无显著性差异；治疗后GPI含量有下降趋势但无统计学意义,与外院研究结果无显著差异。
4结论
4.1 GPI抗原的检测在RA临床诊断、鉴别诊断中具有一定的价值,很可能成为RA临床诊断的一个新指标。
4.2 GPI、抗CCP、AKA、RF4种抗体联合检测对RA有较高的敏感性和特异性,可提高RA的诊断率。
4.3 GPI与RF有显著相关性,由于RF对RA活动性判断有明确的意义,由此推断GPI对RA的诊断及活动性的判断有很大的临床应用价值,有可能和CRP一样,成为RA活动的指标之一
4.4本研究结果显示GPI与RA疗效无显著相关性,对RA疗效评价意义不大；经复方丹参注射液治疗后患者血清中GPI阳性率明显降低且含量有降低趋势,复方丹参注射液对GPI有一定的影响。
1 Objects
1.1 To study serum glucose-6 phosphate isomerase(GPI) level from RA patients, other rheumatologic patients, non-rheumatologic patients and healthy controls. Discuss the role of glucose-6 phosphate isomerase in diagnosis of RA.
1.2 To assess the diagnostic significance of serum GPI, anti-Cyclic Citrullinated Peptide antibody(anti-CCP), anti-keratin antibody(AKA) and rheumatoid factor(RF) in the diagnosis of RA.
1.3 To compare serum GPI, RF, erythrocyte sedimentation rate(ESR), C-reative protein(CRP) of RA patients. Evaluate the relationship among GPI and other factors.
1.4 To study the variation of GPI,RF, ESR, CRP before and after treatment. Evaluate the role of GPI in curative effect evaluation of RA. Evaluate the effect of compound salvia m iltiorrhizal injection on GPI.
2 Methods
2.1 Used Enzyme-Linked Immuno Sorbent Assay to exam serum GPI level from 53 RA patients,35 other rheumatologic patients,30·non-rheumatologic patients and 60 healthy controls.The result of this study was compared.
2.2 Used Enzyme-Linked Immuno Sorbent Assay to exam serum GPI level, anti-CCP, used indirect immunofluoresent assay to exam AKA, used turbidimetric immunoassay method to exam RF from 53 patients of RA. Sum up the sensitivity and specificity for diagnosis of RA.
2.3 Used Enzyme-Linked Immuno Sorbent Assay to exam serum GPI level,used turbidimetric immunoassay method to exam RF and CRP, used westergren to exam ESR from 53 patients of RA. Sum up and compare the result.
2.4 To exam serum GPI level, RF, ESR, CRP from 20 patients of RA before and after the treatment and compare the result. To compare serum GPI level before and after the treatment with othe hospital.
3 Results
3.1 Serum GPI level and the GPI positive rate from RA patients were 3.65±2.87ug/ml and 79.25%, from other rheumatologic patients were 0.96±1.74ug/ml and 40%, from non-rheumatologic patients were 0.40±0.99ug/ml and 20%. The GPI positive rate from healthy controls was 5%. Serum GPI level from RA patients was significantly higher than those from other rheumatologic patients and non-rheumatologic patients. There were significant difference among RA patients and other rheumatologic patients, non-rheumatologic patients. There were no difference between rheumatologic patients and non-rheumatologic patients.
3.2 The sensitivity and specificity of GPI for diagnosis of RA were 79.25% and 69.23%;anti-CCP were 56.6% and 96.92%; AKA were 32.0% and 96.92%; RF were 71.7% and 89.23%. The sensitivity and specificity of the combined detection of GPI,anti-CCP and RF and/or AKA were 88.68% and 100%.
3.3 Compared with RF, the r value was 0.6527. There were significant relationship between GPI and RF (P<0.01). While there were no relationship among GPI and ESR、CRP(P>0.05).
3.4 The main clinical symptoms of the 20 RA patients were improved significantly after the treatment. Serum GPI level, ESR and CRP had no difference between before and after the treatment. Serum GPI level was degraded significantly but was conformity. Compared with other clinical research, the changement of serum GPI level was conformity.
4 Conclusions
4.1 GPI holds great promise as a diagnosis and differential diagnosis tool for RA. It may be a new index for diagnosis of RA.
4.2 The combined detection of GPI, anti-CCP, AKA and RF have high sensitivity and specificity in diagnosis of RA. Thus the combined detection of these four antibodies may help the diagnosis of RA.
4.3 GPI is shown to be significantly related to RF. RF plays a great role on the activity of RA. Thus, GPI holds great promise as a diagnosis tool for RA and its activity. It may be one of the index for activity of RA such as CRP.
4.4 GPI is not shown to be significantly related in curative effect evaluation to RA. The GPI positive rate and serum GPI level from 20 RA patients is degraded significantly after the treatment of compound salvia m iltiorrhizal injection. Compound salvia m iltiorrhizal injection has certain impact on GPI.
引文
[1]Walker JI.Faik P,Morgan MJ. Characterization of the 50 end of the gene for human glucose phosphate isomerase(GPI)[J]. Genomics,1990;7(4):638-43.
[2]Watanbe H, Takehana K, Date M, et al. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide[J]. Cancer Res,1996; 56 (13):2960-3.
[3]Gurney ME, Apatoff BR, Spear GT. Neuroleukin:a lymphokine product of lectinstimulated T cells[J]. Science,1986;234:574-581.
[4]Gurney ME, Heinrich SP, Lee MR, et al. Molecular cloning and expression of neuroleukin, a neurotrophic factor for spinal and sensory neurons[J]. Science,1986;234:566-574.
[5]Xu W, Seiter E, Feldman E, et al. The differention and maturation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phophoglucose isomerase [J]. Blood,1996;87:4502-4506.
[6]Lin HY, Kao YH, Chen ST, et al. Effects of inherited mutations on catalytic activity and structural stability of human glucose-6-phosphate isomerase expressed in Escherichia coli[J].Biochim Biophys Acta,2009;1794(2):315-23.
[7]Kouskoff V, Korganow AS, Duchatelle V, et al. Organ-specific disease provoked by systemic autoimmunity[J]. Cell,1996;87:811-22.
[8]Kim JY, Lee MH, Jung KI, et al. Detection of antibodies against glucose 6-phosphate isomerase in synovial fluid of rheumatoid arthritis using surface plasmon resonance (BIAcore) [J].Exp Mol Med,2003;31;35(4):310-6.
[9]Schubert D, Schmidt M, Zaiss D, et al. Autoantibodies to GPI and creatine kinase in RA[J].Nat Immunol,2002;3(5):411.
[10]Schaller M, Stohl W, Tan SM, et al. Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory artheitis[J].Ann Rherm Dis,2005;64(5):743-9.
[11]Schaller M, Burton, DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis:linkage between an animal model and human disease[J]. Nat Immunol,2001; 2 (8):746-53.
[12]Schaller M, Stohl W.Benoit V, et al. Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase(GPI)[J]. Biochemical&Biophysical Research Communications,2006;349(2):838-845.
[13]Cha HS, Kim TJ, Lee MH, et al. Autoantibidies to glucose-6-phosphate isomerase are elevated in the synovial fluid of rheumatoid arthritis patients[J].Scand J Rheumatol,2004;33:179-184.
[14]赵冠飞,李永哲,王红梅等.血清中葡萄糖6-磷酸异构酶在类风湿关节炎中的诊断意义[J].中国实验诊断学,2007；11(7)：884-886.
[15]Schubert D, Schmidt M, Zaiss D, et al. Autoantibodies to GPI and creatine kinase in RA[J]. NatImmunol,2002;3:411.
[16]Kassahn D,Kolb C, Solomon S, et al. Few human autoimmune sera detect GPI[J]. Nat Immunol,2002;3:411-412.
[17]Matsumoto I, Lee DM, Goldbach-Mansky R, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders[J]. Arthritis Rheum,2003; 48 (4):944-54.
[18]Herve CA, Wait R, Venables PJ. Glucose-6-phosphate isomerase is not a specific autoantigen in rheumatoid arthritis[J]. Rheumatology-(Oxford),2003;42(8):986-8.
[19]Studelska DR, Mandik-Nayak L, Zhou X, et al. High affinity glycosaminoglycan and autoantigen interaction explains joint specificity in a mouse model of rheumatoid arthritis[J]. J Biol Chem,2009;284(4):2354-62.
[20]Solomon S, Kolb C, Mohanty S, et al. Transmission of antibody-induced arthritis is independent of complement component 4(C4)and the complement receptors 1 and 2(CD21/35)[J]. Eur J Immunol,2002;32:644-651.
[21]Shih FF, Racz J, Allen PM. Differential MHC class Ⅱ presentation of a pathogenic autoantigen during health and disease[J]. Journal of Immunology,2006;176(6):3438-48. Wipke BT.
[22]Isao M, Adrien S, Christophe B, et al. Arthritis provoked by linked and B cell recognition of a glycolytic enzyme[J]. Science,1999;286:1732-5.
[23]Schubert D, Maier B, Morawietz L, et al. Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice[J]. Immunol,2004;172(7):4503-9.
[24]Funasaka T, Yanagawa T, Hogan V, et al. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia[J]. FASEB Journal,2005;19(11):1422-1430.
[25]Niizeki H, Kobayashi M, Horiuchi I, et al. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells[J]. British Journal of Cancer,2002;86(12):1914-1919.
[26]Naughton DP. Hypoxia-induced upregulation of the glycolytic enzymee glucose-6-phosphate isomerase perpetuates rheumatoid arthritis[J]. Medical Hypotheses,2003;60(3):332-334.
[27]Butler DM, Malfait AM, Mason LJ, et al. DBA/1 mice expressing the human TNF-a transgene develop a severe, erosive arthritis:characterization of the cytokine cascade and cellular composition[J]. J Immunol,2002;159:2867.
[28]Gondolf KM, Mihatsch, Curschellas J. Induction of experimental allergic arthritis with outer surface proteins of Borrelia burgdorferi [J]. Arthritis Rheum,1994;37:1070.
[29]Kyburz D, Carson DA, Corr M. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis[J]. Arthritis&Rheumatism,2000;43(11):2571-2577.
[30]Kouskoff V, Korganow AS, Duchatelle V, et al.Mathis D. Organ-specific disease provoked by systemic autoimmunity[J]. Cell,1996;87:811-822.
[31]Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis[J]. Journal of Experimental Medicine,2002;196(1):77-85.
[32]Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3,-8,-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis[J]. Annals of the Rheumatic Diseases,2003;62(11):1094-1099.
[33]Yu FL, Liao MH, Lee JW, et al. Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3[J]. Biochem Biophys Res Commun,2004; 314(1):76-82.
[34]Muraki Y, Matsumoto I, Chino Y, et al. Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPI antibodies:possible mechanism of autoantibody production[J]. Biochemical & Bioph-ysical Research Communications,2004;323(2):518-22.
[35]Mandik-Nayak L, Wipke BT, Shih FF, et al. Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node [J]. Proceedings of the National Academy of Sciences of the United States of America,2002;99(22):14368-14373.
[36]Kermann R, Schubert D, Kamradt T, et al. Induction of a B-cell dependent chronic arthritis with glucose-6-phosphate isomerase[J]. Arthritis Res Ther,2005;7:1316-1324.
[37]Wipke BT, Wang Z, Nagengast W, et al. Staging the initiation of autoantibody-induced arthritis:a critical role for immune complexes[J]. J Immunol,2004;172(12):7694-702.
[38]Mandik-Nayak L, Allen PM. Initiation of an autoimmune response:insights from a transgenic model of rheumatoid arthritis[J]. Immunologic Research,2005;32(1-3):5-13.
[39]Hogarth PM. Fc receptors are major mediator of antibody based inflammation in antoimmunity[J]. Curr opin immunol,2002;14:798.
[40]Matsumoto I,Maccioni M, Lee DM. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease[J]. Nature Immunology,2002;3(4):360-365.
[41]Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players[J]. Immunity,2002,16(2):157-168.
[42]卿之驹,贾凯,秦立新.葡萄糖6-磷酸异构酶在类风湿关节炎中的诊断意义[J].实用预防医学,2005：12(3)：481-482.
[43]郭品娥,沈茜,郝怡鑫等.血清6-磷酸葡萄糖异构酶水平对类风湿关节炎的诊断价值[J].诊断学理论与实践,2005：4(6)：466-468.
[44]张明梅,张志智,卢添宝等.类风湿性关节炎中葡萄糖-6-磷酸异构酶的检测及其临床意义[J].同济大学学报(医学版),2007：28(6)：105-108.
[45]曾颖瑜,陶怡.血清中葡萄糖262磷酸异构酶在类风湿关节炎诊断中的意义[J].广州医学院学报,2007：35(4)：1-4.
[46]张爱萍,吴雪花,谭晓华等.类风湿性关节炎患者葡萄糖6-磷酸异构酶的测定及临床价值[J].临床检验杂志,2008：26(2)：142-143.
[47]伊心浩,朱新兴,张旗等.血清葡萄糖6-磷酸异构与自身免疫性疾病相关性研究[J].检验医学,2007：22(2)：182-184.
[48]张铁汉,赵永新,王春燕等.葡萄糖-6-磷酸异构酶与国产抗CCP抗体诊断类风湿关节炎的价值[J].中国实用医药,2008；3(18)：7-9.
[49]张迎梅,林宁,姜玉章等.葡萄糖-6-磷酸异构酶(GPI)检测在类风湿性关节炎诊治中的应用价值[J].现代检验医学杂志,2008；23(4)：77-79.
[50]金跃,张建明,王书建等.6-磷酸葡萄糖异构酶抗原检测在类风湿性关节炎中的诊断价值[J].临床输血与检验,2008：10(2)：122-124.
[51]鲍春德,叶萍,陈晓翔等.血清中6-磷酸葡萄糖异构酶抗原升高在类风湿关节炎中的意义探讨[J].中华风湿病学杂志,2005；9(5)：277-279.
[52]Monica Schaller AE, William Stohl B, Vivian Benoit A, et al. Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexedglucose-6-phosphate isomerase G6PI[J]. Biochemical and Biophysical Research Communications,2006;349:838-845.
[53]潘永煌.血清葡萄糖6-磷酸异构酶检测在类风湿关节炎诊断中的应用[J].中国实用医药,2007；2(36)：75-77.
[54]刘黎,陈晓翔,钱捷等.GPI-mRNA在类风湿关节炎活动期和稳定期及正常人之间表达的研究[J].标记免疫分析与临床,2008；15(4)：234-237.
[55]戎永华.补肾祛湿蠲痹通络法治疗类风湿性关节炎60例疗效观察[J].现代实用医学,2007；19(4)：297-298.
[56]赵蓓俊,陈湘君.陈湘君教授治疗类风湿性关节炎经验[J].河南中医,2009,29(3)：247-248.
[57]俞小芬.中医药治疗类风湿性关节炎的研究进展[J].辽宁中医药大学学报,2008；10(2)：47-48.
[58]高昀,张景贵.中药治疗类风湿性关节炎86例临床体会[J].甘肃中医,2003：16(2)：19-21.
[59]杨国军.中医分型辨治类风湿性关节炎60例[J].现代中医药,2009；29(2)：28-29.
[60]林如祥,韩渝.浅谈类风湿性关节炎中医分型治疗[J].国医论坛,2007；22(1)：16.
[61]田维君.类风湿性关节炎的中医辨证论治[J].西南国防医药,2003：13(6)：635-637.
[62]钱之华,张宏宇.冯兴华中医治疗类风湿性关节炎的经验[J].新中医,1999：31(12)：6-7.
[63]王智明.张延昌治类风湿性关节炎学术探讨[J].中医药通报,2009；8(1)：15-17.
[64]宫险峰.类风湿关节炎辨证治疗临床体会[J].光明中医,2008；23(7)：1009-1010.
[65]闫惠霞,马立森,李秋菊等.中医综合疗法辨治类风湿性关节炎68例[J].中医研究,2008：21(10)：42-43.
[66]郜中明.中医辩证治疗类风湿性关节炎82例[J].四川中医,2006；24(8)：64.
[67]刘晓英.中西医结合治疗类风湿性关节炎体会[J].基层医学论坛,2008：12(5)：445-446.
[68]孔海云,窦永起.论类风湿性关节炎的辨病与辨证治疗[J].实用中西医结合杂志,1995：8(4)：198-199.
[69]黎明.分期治疗类风湿性关节炎272例[J].湖南中医杂志,1999；15(3)：49.
[70]郭凤莲.分期辨证治疗类风湿性关节炎50例[J].中华实用中西医杂志,1998：11(9)：781-782.
[71]肖泓,吴永听,吴生元.吴生元辨治类风湿性关节炎的经验[J].云南中医中药杂志,2009；30(4)：1-2.
[72]续青,王健,刘永红.桂枝芍药知母汤加味治疗类风湿性关节炎临床疗效观察[J].中国现代医学杂志,2004：14(8)：140-141,145.
[73]李晓华,唐雪峰.补阳还五合剂治疗类风湿性关节炎临床观察[J].山东中医杂志,2003：22(1)：13-14.
[74]王海松.温肾通痹汤治疗类风湿性关节炎临床研究[J].辽宁中医志,2006：33(1)：56-57.
[75]陈秀芳,金晨宇.桂乌汤对类风湿性关节炎的内分泌免疫调节作用[J].浙江中西医结合杂志,2008：18(1)：6-8.
[76]何维夏.复方丹参注射液治疗类风湿性关节炎25例[J].中国中医急症,2005：14(8)：746.
[77]刘晓玲,陈纪藩,邓健等.二藤通痹合剂治疗类风湿性关节炎162例疗效观察[J].中药新药与临床药理,2005：16(4)：294-295.
[78]马小平.五藤胶囊治疗类风湿性关节炎43例[J].上海中医药杂志,2004：38(8)：29-30.
[79]张洪峰,肖卫国.疏血通注射液治疗活动期类风湿关节炎的临床观察[J].中国中西医结合杂志,2008：28(3)：255-257.
[80]姜泉,焦娟.清热活血法外治类风湿关节炎疗效观察[J].中医正骨,2006：18(3)：21-22.
[81]应森林,孟静岩,李尚珠等.解毒消瘀膏外治类风湿性关节炎的临床观察[J].天津中医,2001：18(2)：17-19.
[82]张秋万.中药内服加外用治疗类风湿性关节炎60例[J].山西中医学院学报,2006,7(2)：21.
[83]王德萍,刘燕平.双柏散外敷为主治疗类风湿关节炎40例[J].湖南中医杂志,2002；18(3)：50-51.
[84]姚海春,姚京辉,陈云等.活蜂螫刺治疗类风湿性关节炎98例[J].中国针灸,2008：28(5)：395-396.
[85]左芳,刘维,王慧.新癀片配合针刺治疗类风湿关节炎62例[J].天津中医药,2004；21(4)：295.
[86]于水莲,沈鹰.中药熏蒸治疗活动期类风湿性关节炎临床疗效评价[J].中国临床保健杂志,2008：11(4)：337-340.
[87]郭爱华,曲晶晶.穴位埋线治疗类风湿性关节炎6例[J].中国煤炭工业医学杂 志,2005：8(6)：558.
[88]邱玉珍,张爱华.中西医治疗类风湿性关节炎近况[J].中国中医急症,2008：17(1)：98-100.
[89]黄清春,接力刚.浅谈复方丹参注射液治疗类风湿性关节炎的机理.中医杂志,2006：47(6)：476-477.
[90]訾慧.中药降香研究进展[J].辽宁中医学院学报,2003；5(2)：90-91.
[91]张旭.复方丹参穴位注射治疗肩关节周围炎37例[J].人民军医,2004；47(10)：618-619.
[92]葛成栋,李锋.复方丹参注射液治疗骨关节炎63例临床分析[J].中国实用乡村医生杂志,2004；11(2)：32-33.
[93]谭志明.复方丹参注射液不同剂量穴位注射对强直性脊柱炎患者疼痛及关节活动度的影响[J].中国临床康复,2004；8(26)：5610-5611.
[94]黄清春,储永良,接力刚等.复方丹参注射液对RF滑膜细胞VEGFmRNA的影响[J].安徽中医学院学报.2007,26(1)：41-43.
[95]储永良,黄清春.痹病从瘀论治[J].中国中医药信息杂志.2006；13(4)：7-8.
[96]沈鹰,黄清春,接力刚等.复方丹参注射液治疗风湿性疾病的研究[J].华南国防医学杂志：2007,21(6)：15-18.
[97]Matsumoto I, Staub A, Benoist C, er al. Arthritis provoked by tinked T and B cell recognition of a glycolytic enzyme[J]. Science,1999;286:1732-1735.
[2]Watanbe H, Takehana K, Date M, et al. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide[J]. Cancer Res,1996; 56 (13):2960-3.
[3]Gurney ME, Apatoff BR, Spear GT. Neuroleukin:a lymphokine product of lectinstimulated T cells[J]. Science,1986;234:574-581.
[4]Gurney ME, Heinrich SP, Lee MR, et al. Molecular cloning and expression of neuroleukin, a neurotrophic factor for spinal and sensory neurons[J]. Science,1986;234:566-574.
[5]Xu W, Seiter E, Feldman E, et al. The differention and maturation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phophoglucose isomerase [J]. Blood,1996;87:4502-4506.
[6]Lin HY, Kao YH, Chen ST, et al. Effects of inherited mutations on catalytic activity and structural stability of human glucose-6-phosphate isomerase expressed in Escherichia coli[J].Biochim Biophys Acta,2009;1794(2):315-23.
[7]Kouskoff V, Korganow AS, Duchatelle V, et al. Organ-specific disease provoked by systemic autoimmunity[J]. Cell,1996;87:811-22.
[8]Kim JY, Lee MH, Jung KI, et al. Detection of antibodies against glucose 6-phosphate isomerase in synovial fluid of rheumatoid arthritis using surface plasmon resonance (BIAcore) [J].Exp Mol Med,2003;31;35(4):310-6.
[9]Schubert D, Schmidt M, Zaiss D, et al. Autoantibodies to GPI and creatine kinase in RA[J].Nat Immunol,2002;3(5):411.
[10]Schaller M, Stohl W, Tan SM, et al. Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory artheitis[J].Ann Rherm Dis,2005;64(5):743-9.
[11]Schaller M, Burton, DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis:linkage between an animal model and human disease[J]. Nat Immunol,2001; 2 (8):746-53.
[12]Schaller M, Stohl W.Benoit V, et al. Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase(GPI)[J]. Biochemical&Biophysical Research Communications,2006;349(2):838-845.
[13]Cha HS, Kim TJ, Lee MH, et al. Autoantibidies to glucose-6-phosphate isomerase are elevated in the synovial fluid of rheumatoid arthritis patients[J].Scand J Rheumatol,2004;33:179-184.
[14]赵冠飞,李永哲,王红梅等.血清中葡萄糖6-磷酸异构酶在类风湿关节炎中的诊断意义[J].中国实验诊断学,2007；11(7)：884-886.
[15]Schubert D, Schmidt M, Zaiss D, et al. Autoantibodies to GPI and creatine kinase in RA[J]. NatImmunol,2002;3:411.
[16]Kassahn D,Kolb C, Solomon S, et al. Few human autoimmune sera detect GPI[J]. Nat Immunol,2002;3:411-412.
[17]Matsumoto I, Lee DM, Goldbach-Mansky R, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders[J]. Arthritis Rheum,2003; 48 (4):944-54.
[18]Herve CA, Wait R, Venables PJ. Glucose-6-phosphate isomerase is not a specific autoantigen in rheumatoid arthritis[J]. Rheumatology-(Oxford),2003;42(8):986-8.
[19]Studelska DR, Mandik-Nayak L, Zhou X, et al. High affinity glycosaminoglycan and autoantigen interaction explains joint specificity in a mouse model of rheumatoid arthritis[J]. J Biol Chem,2009;284(4):2354-62.
[20]Solomon S, Kolb C, Mohanty S, et al. Transmission of antibody-induced arthritis is independent of complement component 4(C4)and the complement receptors 1 and 2(CD21/35)[J]. Eur J Immunol,2002;32:644-651.
[21]Shih FF, Racz J, Allen PM. Differential MHC class Ⅱ presentation of a pathogenic autoantigen during health and disease[J]. Journal of Immunology,2006;176(6):3438-48. Wipke BT.
[22]Isao M, Adrien S, Christophe B, et al. Arthritis provoked by linked and B cell recognition of a glycolytic enzyme[J]. Science,1999;286:1732-5.
[23]Schubert D, Maier B, Morawietz L, et al. Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice[J]. Immunol,2004;172(7):4503-9.
[24]Funasaka T, Yanagawa T, Hogan V, et al. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia[J]. FASEB Journal,2005;19(11):1422-1430.
[25]Niizeki H, Kobayashi M, Horiuchi I, et al. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells[J]. British Journal of Cancer,2002;86(12):1914-1919.
[26]Naughton DP. Hypoxia-induced upregulation of the glycolytic enzymee glucose-6-phosphate isomerase perpetuates rheumatoid arthritis[J]. Medical Hypotheses,2003;60(3):332-334.
[27]Butler DM, Malfait AM, Mason LJ, et al. DBA/1 mice expressing the human TNF-a transgene develop a severe, erosive arthritis:characterization of the cytokine cascade and cellular composition[J]. J Immunol,2002;159:2867.
[28]Gondolf KM, Mihatsch, Curschellas J. Induction of experimental allergic arthritis with outer surface proteins of Borrelia burgdorferi [J]. Arthritis Rheum,1994;37:1070.
[29]Kyburz D, Carson DA, Corr M. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis[J]. Arthritis&Rheumatism,2000;43(11):2571-2577.
[30]Kouskoff V, Korganow AS, Duchatelle V, et al.Mathis D. Organ-specific disease provoked by systemic autoimmunity[J]. Cell,1996;87:811-822.
[31]Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis[J]. Journal of Experimental Medicine,2002;196(1):77-85.
[32]Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3,-8,-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis[J]. Annals of the Rheumatic Diseases,2003;62(11):1094-1099.
[33]Yu FL, Liao MH, Lee JW, et al. Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3[J]. Biochem Biophys Res Commun,2004; 314(1):76-82.
[34]Muraki Y, Matsumoto I, Chino Y, et al. Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPI antibodies:possible mechanism of autoantibody production[J]. Biochemical & Bioph-ysical Research Communications,2004;323(2):518-22.
[35]Mandik-Nayak L, Wipke BT, Shih FF, et al. Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node [J]. Proceedings of the National Academy of Sciences of the United States of America,2002;99(22):14368-14373.
[36]Kermann R, Schubert D, Kamradt T, et al. Induction of a B-cell dependent chronic arthritis with glucose-6-phosphate isomerase[J]. Arthritis Res Ther,2005;7:1316-1324.
[37]Wipke BT, Wang Z, Nagengast W, et al. Staging the initiation of autoantibody-induced arthritis:a critical role for immune complexes[J]. J Immunol,2004;172(12):7694-702.
[38]Mandik-Nayak L, Allen PM. Initiation of an autoimmune response:insights from a transgenic model of rheumatoid arthritis[J]. Immunologic Research,2005;32(1-3):5-13.
[39]Hogarth PM. Fc receptors are major mediator of antibody based inflammation in antoimmunity[J]. Curr opin immunol,2002;14:798.
[40]Matsumoto I,Maccioni M, Lee DM. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease[J]. Nature Immunology,2002;3(4):360-365.
[41]Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players[J]. Immunity,2002,16(2):157-168.
[42]卿之驹,贾凯,秦立新.葡萄糖6-磷酸异构酶在类风湿关节炎中的诊断意义[J].实用预防医学,2005：12(3)：481-482.
[43]郭品娥,沈茜,郝怡鑫等.血清6-磷酸葡萄糖异构酶水平对类风湿关节炎的诊断价值[J].诊断学理论与实践,2005：4(6)：466-468.
[44]张明梅,张志智,卢添宝等.类风湿性关节炎中葡萄糖-6-磷酸异构酶的检测及其临床意义[J].同济大学学报(医学版),2007：28(6)：105-108.
[45]曾颖瑜,陶怡.血清中葡萄糖262磷酸异构酶在类风湿关节炎诊断中的意义[J].广州医学院学报,2007：35(4)：1-4.
[46]张爱萍,吴雪花,谭晓华等.类风湿性关节炎患者葡萄糖6-磷酸异构酶的测定及临床价值[J].临床检验杂志,2008：26(2)：142-143.
[47]伊心浩,朱新兴,张旗等.血清葡萄糖6-磷酸异构与自身免疫性疾病相关性研究[J].检验医学,2007：22(2)：182-184.
[48]张铁汉,赵永新,王春燕等.葡萄糖-6-磷酸异构酶与国产抗CCP抗体诊断类风湿关节炎的价值[J].中国实用医药,2008；3(18)：7-9.
[49]张迎梅,林宁,姜玉章等.葡萄糖-6-磷酸异构酶(GPI)检测在类风湿性关节炎诊治中的应用价值[J].现代检验医学杂志,2008；23(4)：77-79.
[50]金跃,张建明,王书建等.6-磷酸葡萄糖异构酶抗原检测在类风湿性关节炎中的诊断价值[J].临床输血与检验,2008：10(2)：122-124.
[51]鲍春德,叶萍,陈晓翔等.血清中6-磷酸葡萄糖异构酶抗原升高在类风湿关节炎中的意义探讨[J].中华风湿病学杂志,2005；9(5)：277-279.
[52]Monica Schaller AE, William Stohl B, Vivian Benoit A, et al. Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexedglucose-6-phosphate isomerase G6PI[J]. Biochemical and Biophysical Research Communications,2006;349:838-845.
[53]潘永煌.血清葡萄糖6-磷酸异构酶检测在类风湿关节炎诊断中的应用[J].中国实用医药,2007；2(36)：75-77.
[54]刘黎,陈晓翔,钱捷等.GPI-mRNA在类风湿关节炎活动期和稳定期及正常人之间表达的研究[J].标记免疫分析与临床,2008；15(4)：234-237.
[55]戎永华.补肾祛湿蠲痹通络法治疗类风湿性关节炎60例疗效观察[J].现代实用医学,2007；19(4)：297-298.
[56]赵蓓俊,陈湘君.陈湘君教授治疗类风湿性关节炎经验[J].河南中医,2009,29(3)：247-248.
[57]俞小芬.中医药治疗类风湿性关节炎的研究进展[J].辽宁中医药大学学报,2008；10(2)：47-48.
[58]高昀,张景贵.中药治疗类风湿性关节炎86例临床体会[J].甘肃中医,2003：16(2)：19-21.
[59]杨国军.中医分型辨治类风湿性关节炎60例[J].现代中医药,2009；29(2)：28-29.
[60]林如祥,韩渝.浅谈类风湿性关节炎中医分型治疗[J].国医论坛,2007；22(1)：16.
[61]田维君.类风湿性关节炎的中医辨证论治[J].西南国防医药,2003：13(6)：635-637.
[62]钱之华,张宏宇.冯兴华中医治疗类风湿性关节炎的经验[J].新中医,1999：31(12)：6-7.
[63]王智明.张延昌治类风湿性关节炎学术探讨[J].中医药通报,2009；8(1)：15-17.
[64]宫险峰.类风湿关节炎辨证治疗临床体会[J].光明中医,2008；23(7)：1009-1010.
[65]闫惠霞,马立森,李秋菊等.中医综合疗法辨治类风湿性关节炎68例[J].中医研究,2008：21(10)：42-43.
[66]郜中明.中医辩证治疗类风湿性关节炎82例[J].四川中医,2006；24(8)：64.
[67]刘晓英.中西医结合治疗类风湿性关节炎体会[J].基层医学论坛,2008：12(5)：445-446.
[68]孔海云,窦永起.论类风湿性关节炎的辨病与辨证治疗[J].实用中西医结合杂志,1995：8(4)：198-199.
[69]黎明.分期治疗类风湿性关节炎272例[J].湖南中医杂志,1999；15(3)：49.
[70]郭凤莲.分期辨证治疗类风湿性关节炎50例[J].中华实用中西医杂志,1998：11(9)：781-782.
[71]肖泓,吴永听,吴生元.吴生元辨治类风湿性关节炎的经验[J].云南中医中药杂志,2009；30(4)：1-2.
[72]续青,王健,刘永红.桂枝芍药知母汤加味治疗类风湿性关节炎临床疗效观察[J].中国现代医学杂志,2004：14(8)：140-141,145.
[73]李晓华,唐雪峰.补阳还五合剂治疗类风湿性关节炎临床观察[J].山东中医杂志,2003：22(1)：13-14.
[74]王海松.温肾通痹汤治疗类风湿性关节炎临床研究[J].辽宁中医志,2006：33(1)：56-57.
[75]陈秀芳,金晨宇.桂乌汤对类风湿性关节炎的内分泌免疫调节作用[J].浙江中西医结合杂志,2008：18(1)：6-8.
[76]何维夏.复方丹参注射液治疗类风湿性关节炎25例[J].中国中医急症,2005：14(8)：746.
[77]刘晓玲,陈纪藩,邓健等.二藤通痹合剂治疗类风湿性关节炎162例疗效观察[J].中药新药与临床药理,2005：16(4)：294-295.
[78]马小平.五藤胶囊治疗类风湿性关节炎43例[J].上海中医药杂志,2004：38(8)：29-30.
[79]张洪峰,肖卫国.疏血通注射液治疗活动期类风湿关节炎的临床观察[J].中国中西医结合杂志,2008：28(3)：255-257.
[80]姜泉,焦娟.清热活血法外治类风湿关节炎疗效观察[J].中医正骨,2006：18(3)：21-22.
[81]应森林,孟静岩,李尚珠等.解毒消瘀膏外治类风湿性关节炎的临床观察[J].天津中医,2001：18(2)：17-19.
[82]张秋万.中药内服加外用治疗类风湿性关节炎60例[J].山西中医学院学报,2006,7(2)：21.
[83]王德萍,刘燕平.双柏散外敷为主治疗类风湿关节炎40例[J].湖南中医杂志,2002；18(3)：50-51.
[84]姚海春,姚京辉,陈云等.活蜂螫刺治疗类风湿性关节炎98例[J].中国针灸,2008：28(5)：395-396.
[85]左芳,刘维,王慧.新癀片配合针刺治疗类风湿关节炎62例[J].天津中医药,2004；21(4)：295.
[86]于水莲,沈鹰.中药熏蒸治疗活动期类风湿性关节炎临床疗效评价[J].中国临床保健杂志,2008：11(4)：337-340.
[87]郭爱华,曲晶晶.穴位埋线治疗类风湿性关节炎6例[J].中国煤炭工业医学杂 志,2005：8(6)：558.
[88]邱玉珍,张爱华.中西医治疗类风湿性关节炎近况[J].中国中医急症,2008：17(1)：98-100.
[89]黄清春,接力刚.浅谈复方丹参注射液治疗类风湿性关节炎的机理.中医杂志,2006：47(6)：476-477.
[90]訾慧.中药降香研究进展[J].辽宁中医学院学报,2003；5(2)：90-91.
[91]张旭.复方丹参穴位注射治疗肩关节周围炎37例[J].人民军医,2004；47(10)：618-619.
[92]葛成栋,李锋.复方丹参注射液治疗骨关节炎63例临床分析[J].中国实用乡村医生杂志,2004；11(2)：32-33.
[93]谭志明.复方丹参注射液不同剂量穴位注射对强直性脊柱炎患者疼痛及关节活动度的影响[J].中国临床康复,2004；8(26)：5610-5611.
[94]黄清春,储永良,接力刚等.复方丹参注射液对RF滑膜细胞VEGFmRNA的影响[J].安徽中医学院学报.2007,26(1)：41-43.
[95]储永良,黄清春.痹病从瘀论治[J].中国中医药信息杂志.2006；13(4)：7-8.
[96]沈鹰,黄清春,接力刚等.复方丹参注射液治疗风湿性疾病的研究[J].华南国防医学杂志：2007,21(6)：15-18.
[97]Matsumoto I, Staub A, Benoist C, er al. Arthritis provoked by tinked T and B cell recognition of a glycolytic enzyme[J]. Science,1999;286:1732-1735.